Factor VIII protein (FVIII) as a coagulation replacement factor has for decades been used as
the standard of care for management of people with haemophilia A. It is effective for …

Objective To review the current knowledge on bone health in patients with hemophilia A and
the underlying pathogenetic mechanisms. Data Sources Original research articles, meta …

Haemophilic arthropathy (HA), caused by intra-articular haemorrhage, is one of the most
common complications in patients with haemophilia. Factor replacement therapy provides …

Although haemophilia is not considered among the classic causes of secondary
osteoporosis, the present meta-analysis provides strong evidence that men with …

Joint health is a key contributor to quality of life in patients with hemophilia. However,
variables that impact long-term joint outcomes have not been comprehensively defined. A …

Hemophilia A is an X-linked hereditary disorder that results from deficient coagulation factor
VIII (FVIII) activity, leading to spontaneous bleeding episodes, particularly in joints and …

Introduction Patients with haemophilia (PWH) have a high prevalence of osteoporosis, falls
and fractures at all ages. The role of haemophilia itself may contribute to low bone mineral …

With the introduction of clotting factor concentrates in the early 1970s, significant
improvements in quality of life and life expectancy of persons with haemophilia (PWH) were …

Background: Hemophilia A and B are X-linked congenital bleeding disorders characterized
by recurrent hemarthroses leading to specific changes in the synovium and cartilage, which …

Objectives: To assess the effects of short-term resistance training and pulsed
electromagnetic fields on bone metabolism and joint function in patients with haemophilia …